[Human umbilical cord blood transplantation in 4 cases with advanced solid tumors].
Four patients with solid tumors were treated with high dose chemotherapy and HLA-mismatched multi-cord blood transplantation. Of them, 3 reached complete remission, 1 got fair response. The side effects were tolerable. Little or no graft-versus-host reaction (GVHR) was observed. Donor cell engraftment was documented in 2 patients by cytogenetic analysis and determination of hemoglobin F of the peripheral blood. Recurrent diseases were confirmed clinically on day 210 (4 year-old girl with liposarcoma) and day 90 (11 year-old boy with non-Hodgkin's lymphoma). These results demonstrated that HLA-mismatched multicord blood transfusion could rescue myelo-suppression of patients treated with myeloablative chemotherapy. Therefore, cord blood may serve as a rich source of hematopoietic stem cells.
Shen
B J
BJ
Shandong Medical University Hospital, Jinan.
D016913:Blood Component Transfusion / Q000379:methods; D001803:Blood Transfusion; D002648:Child; D002675:Child, Preschool; D005260:Female; D005312:Fetal Blood / Q000166:cytology; D018380:Hematopoietic Stem Cell Transplantation; D006801:Humans; D008080:Liposarcoma / Q000628:therapy; D008223:Lymphoma / Q000628:therapy; D008297:Male; D009369:Neoplasms / Q000628:therapy*; D009447:Neuroblastoma / Q000628:therapy; D010051:Ovarian Neoplasms / Q000628:therapy; D010386:Pelvic Neoplasms / Q000628:therapy; D012186:Retroperitoneal Neoplasms / Q000628:therapy; D013724:Teratoma / Q000628:therapy